348626-48-2

Basic information

• Product Name: benzyl [4-(2-oxopyrrolidin-1-yl)phenyl]carbamate
• Synonyms: benzyl [4-(2-oxopyrrolidin-1-yl)phenyl]carbamate
• CAS NO: 348626-48-2
• Molecular Weight: 310.353
• Mol File: 348626-48-2.mol

Chemical Properties

• CAS DataBase Reference: benzyl [4-(2-oxopyrrolidin-1-yl)phenyl]carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl [4-(2-oxopyrrolidin-1-yl)phenyl]carbamate(348626-48-2)
• EPA Substance Registry System: benzyl [4-(2-oxopyrrolidin-1-yl)phenyl]carbamate(348626-48-2)

Safety Data

• Hazardous Substances Data: 348626-48-2(Hazardous Substances Data)

Upstream product

• 13691-22-0 1-(4-aminophenyl)pyrrolidin-2-one 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 348626-49-3 (5R)-5-(hydroxymethyl)-3-[4-(2-oxopyrrolidin-1-yl)phenyl]-1,3-oxazolidin-2-one 
• 348626-50-6 (5S)-5-(aminomethyl)-3-[4-(2-oxopyrrolidin-1-yl)phenyl]-1,3-oxazolidin-2-one 

Relevant articles and documents

COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES

The present invention relates to combinations of A) oxazolidinones of the formula (I) with B) acetylsalicylic acid (aspirin) and C) an ADP receptor antagonist, in particular P2Y12 purinoreceptor blocker, to a process for producing these combinations and to the use thereof as medicaments, in particular for the prophylaxis and/or treatment of thromboembolic disorders.

MICROANGIOPATHY TREATMENT AND PREVENTION

The present invention relates to the use of selective factor Xa inhibitors, in particular of oxazolidinones of the formula (I) for the treatment and/or prophylaxis of microangiopathies and also their use for the production of medicaments for the treatment and/or prophylaxis of microangiopathies.

Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders

The present invention relates to combinations of A) oxazolidinones of the formula (I), with B) antiarrhythmics, processes for the production of these combinations, their use for the prophylaxis and/or treatment of diseases, and their use for the manufacture of medicaments for the prophylaxis and/or treatment of diseases, especially of thromboembolic disorders and/or complications.

Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4- (3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): An oral, direct factor Xa inhibitor

Despite recent progress in antithrombotic therapy, there is still an unmet medical need for safe and orally available anticoagulants. The coagulation enzyme Factor Xa (FXa) is a particularly promising target, and recent efforts in this field have focused on the identification of small-molecule inhibitors with good oral bioavailability. We identified oxazolidinone derivatives as a new class of potent FXa inhibitors. Lead optimization led to the discovery of BAY 59-7939 (5), a highly potent and selective, direct FXa inhibitor with excellent in vivo antithrombotic activity. The X-ray crystal structure of 5 in complex with human FXa clarified the binding mode and the stringent requirements for high affinity. The interaction of the neutral ligand chlorothiophene in the S1 subsite allows for the combination of good oral bioavailability and high potency for nonbasic 5. Compound 5 is currently under clinical development for the prevention and treatment of thromboembolic diseases.

Substituted oxazolidinones and their in the field of blood coagulation

The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.